维生素基水包油纳米乳剂的构建增强了伪狂犬病毒灭活疫苗的免疫原性

IF 2.4 3区 医学 Q3 VIROLOGY
Wenzhu Yin , Chen Chang , Yalu Zhu , Fang Ma , Haiyan Wang , Yu Lu , Bo Tang , Bihua Deng
{"title":"维生素基水包油纳米乳剂的构建增强了伪狂犬病毒灭活疫苗的免疫原性","authors":"Wenzhu Yin ,&nbsp;Chen Chang ,&nbsp;Yalu Zhu ,&nbsp;Fang Ma ,&nbsp;Haiyan Wang ,&nbsp;Yu Lu ,&nbsp;Bo Tang ,&nbsp;Bihua Deng","doi":"10.1016/j.virol.2025.110616","DOIUrl":null,"url":null,"abstract":"<div><div>Despite being a common way to prevent infection with the pseudorabies virus (PRV), inactivated vaccines are less effective because of their poor immunogenicity. Adjuvants, as an important component of vaccines, can greatly boost and alter the immune response. In this study, a newly oil-in-water nano-emulsion adjuvant OEBB containing 20 % vitamin E, 30 % Tween-80, and 50 % 1,3-propylene didecanoate was easily prepared with a good thermal stability and biosafety. Combining an inactivated PRV (10<sup>7</sup> TCID50/20 μL) with OEBB, the inactivated OEBB/PRV nano-vaccine with the effective particle diameter of 194.01 ± 59.54 nm was formulated. It displayed a good temperature stability and maintained the particle size within 28 days. Then, the OEBB/PRV nano-vaccine was evaluated for its safety and immunization effect using mice and piglets. The results showed that the OEBB/PRV nano-vaccine significantly increased model animals’ antibody and cytokines. The neutralizing antibody was higher than PRV alone but there was no significantly difference from commercial adjuvant ISA201. Moreover, the challenge protection rate can reach 80 %, which was obviously superior to that of ISA201 (70 %). Safety tests found no hemolytic side effects, no symptoms of PRV or significant toxic reactions, and no damage to organs. The OEBB could enhance the activation of antigen-presenting cells in the local injection skin to deliver the PRV antigen to nearby lymph nodes. This led to increase CD3<sup>+</sup> population and promote differentiation to CD4<sup>+</sup> and CD8<sup>+</sup>, which ultimately induced humoral and cellular immunity. The as-prepared OEBB in this study is an effective adjuvant for PRV inactivated vaccine.</div></div>","PeriodicalId":23666,"journal":{"name":"Virology","volume":"610 ","pages":"Article 110616"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Construction of vitamin E-based oil-in-water nano-emulsion adjuvant enhances immunogenicity of inactivated pseudorabies virus vaccine\",\"authors\":\"Wenzhu Yin ,&nbsp;Chen Chang ,&nbsp;Yalu Zhu ,&nbsp;Fang Ma ,&nbsp;Haiyan Wang ,&nbsp;Yu Lu ,&nbsp;Bo Tang ,&nbsp;Bihua Deng\",\"doi\":\"10.1016/j.virol.2025.110616\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Despite being a common way to prevent infection with the pseudorabies virus (PRV), inactivated vaccines are less effective because of their poor immunogenicity. Adjuvants, as an important component of vaccines, can greatly boost and alter the immune response. In this study, a newly oil-in-water nano-emulsion adjuvant OEBB containing 20 % vitamin E, 30 % Tween-80, and 50 % 1,3-propylene didecanoate was easily prepared with a good thermal stability and biosafety. Combining an inactivated PRV (10<sup>7</sup> TCID50/20 μL) with OEBB, the inactivated OEBB/PRV nano-vaccine with the effective particle diameter of 194.01 ± 59.54 nm was formulated. It displayed a good temperature stability and maintained the particle size within 28 days. Then, the OEBB/PRV nano-vaccine was evaluated for its safety and immunization effect using mice and piglets. The results showed that the OEBB/PRV nano-vaccine significantly increased model animals’ antibody and cytokines. The neutralizing antibody was higher than PRV alone but there was no significantly difference from commercial adjuvant ISA201. Moreover, the challenge protection rate can reach 80 %, which was obviously superior to that of ISA201 (70 %). Safety tests found no hemolytic side effects, no symptoms of PRV or significant toxic reactions, and no damage to organs. The OEBB could enhance the activation of antigen-presenting cells in the local injection skin to deliver the PRV antigen to nearby lymph nodes. This led to increase CD3<sup>+</sup> population and promote differentiation to CD4<sup>+</sup> and CD8<sup>+</sup>, which ultimately induced humoral and cellular immunity. The as-prepared OEBB in this study is an effective adjuvant for PRV inactivated vaccine.</div></div>\",\"PeriodicalId\":23666,\"journal\":{\"name\":\"Virology\",\"volume\":\"610 \",\"pages\":\"Article 110616\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0042682225002296\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0042682225002296","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

尽管灭活疫苗是预防伪狂犬病毒(PRV)感染的常用方法,但由于其免疫原性较差,因此效果较差。佐剂作为疫苗的重要组成部分,可以极大地增强和改变免疫反应。本研究制备了一种新型水包油纳米乳液助剂OEBB,该助剂含有20%的维生素E、30%的吐温-80和50%的1,3-二癸酸丙烯,具有良好的热稳定性和生物安全性。将灭活PRV (107 TCID50/20 μL)与OEBB结合,制得有效粒径为194.01±59.54 nm的OEBB/PRV灭活纳米疫苗。温度稳定性好,28天内保持粒径不变。然后,用小鼠和仔猪对OEBB/PRV纳米疫苗的安全性和免疫效果进行了评价。结果表明,OEBB/PRV纳米疫苗显著提高了模型动物的抗体和细胞因子水平。中和抗体高于单独的PRV,但与商业佐剂ISA201无显著差异。且攻毒保护率可达80%,明显优于ISA201的70%。安全性测试没有发现溶血副作用,没有PRV症状或明显的毒性反应,也没有对器官造成损害。OEBB可以增强局部注射皮肤抗原呈递细胞的活化,将PRV抗原传递到附近淋巴结。这导致CD3+群体增加,并促进向CD4+和CD8+分化,最终诱导体液和细胞免疫。本研究制备的OEBB是PRV灭活疫苗的有效佐剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Construction of vitamin E-based oil-in-water nano-emulsion adjuvant enhances immunogenicity of inactivated pseudorabies virus vaccine

Construction of vitamin E-based oil-in-water nano-emulsion adjuvant enhances immunogenicity of inactivated pseudorabies virus vaccine
Despite being a common way to prevent infection with the pseudorabies virus (PRV), inactivated vaccines are less effective because of their poor immunogenicity. Adjuvants, as an important component of vaccines, can greatly boost and alter the immune response. In this study, a newly oil-in-water nano-emulsion adjuvant OEBB containing 20 % vitamin E, 30 % Tween-80, and 50 % 1,3-propylene didecanoate was easily prepared with a good thermal stability and biosafety. Combining an inactivated PRV (107 TCID50/20 μL) with OEBB, the inactivated OEBB/PRV nano-vaccine with the effective particle diameter of 194.01 ± 59.54 nm was formulated. It displayed a good temperature stability and maintained the particle size within 28 days. Then, the OEBB/PRV nano-vaccine was evaluated for its safety and immunization effect using mice and piglets. The results showed that the OEBB/PRV nano-vaccine significantly increased model animals’ antibody and cytokines. The neutralizing antibody was higher than PRV alone but there was no significantly difference from commercial adjuvant ISA201. Moreover, the challenge protection rate can reach 80 %, which was obviously superior to that of ISA201 (70 %). Safety tests found no hemolytic side effects, no symptoms of PRV or significant toxic reactions, and no damage to organs. The OEBB could enhance the activation of antigen-presenting cells in the local injection skin to deliver the PRV antigen to nearby lymph nodes. This led to increase CD3+ population and promote differentiation to CD4+ and CD8+, which ultimately induced humoral and cellular immunity. The as-prepared OEBB in this study is an effective adjuvant for PRV inactivated vaccine.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Virology
Virology 医学-病毒学
CiteScore
6.00
自引率
0.00%
发文量
157
审稿时长
50 days
期刊介绍: Launched in 1955, Virology is a broad and inclusive journal that welcomes submissions on all aspects of virology including plant, animal, microbial and human viruses. The journal publishes basic research as well as pre-clinical and clinical studies of vaccines, anti-viral drugs and their development, anti-viral therapies, and computational studies of virus infections. Any submission that is of broad interest to the community of virologists/vaccinologists and reporting scientifically accurate and valuable research will be considered for publication, including negative findings and multidisciplinary work.Virology is open to reviews, research manuscripts, short communication, registered reports as well as follow-up manuscripts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信